Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Biologics For Early Rheumatoid Arthritis
Download Biologics For Early Rheumatoid Arthritis full books in PDF, epub, and Kindle. Read online Biologics For Early Rheumatoid Arthritis ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Early Rheumatoid Arthritis by : Paul Emery
Download or read book Early Rheumatoid Arthritis written by Paul Emery and published by . This book was released on 2005 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This issue covers the latest developments in the understanding of rheumatoid arthritis at the early stage. Treatments such as with newer biologic agents and conventional disease-modifying antirheumatic drugs are reviewed. Also included are articles on imaging modalities as a means of identifying those in the early stages and monitoring response to treatment.
Book Synopsis Biologics for Early Rheumatoid Arthritis by :
Download or read book Biologics for Early Rheumatoid Arthritis written by and published by . This book was released on 2011 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Biologics for the Treatment of Rheumatoid Arthritis by : Ronald van Vollenhoven
Download or read book Biologics for the Treatment of Rheumatoid Arthritis written by Ronald van Vollenhoven and published by Springer. This book was released on 2015-12-22 with total page 139 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive overview of the available biologic therapies whilst comparing them to standard disease modifying anti-rheumatic drugs, and discusses how best to determine which therapy is most appropriate for an individual patient in the framework of current guidelines. Biologics for the Treatment of Rheumatoid Arthritis is an up-to-date and concise practical guide to the latest therapeutic developments in this field. This book is an invaluable source of topical information for all rheumatologists and health care professionals treating patients with rheumatoid arthritis.
Book Synopsis Biologics for Early Rheumatoid Arhritis by :
Download or read book Biologics for Early Rheumatoid Arhritis written by and published by . This book was released on 2010 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Rheumatoid Arthritis by : John J. Cush
Download or read book Rheumatoid Arthritis written by John J. Cush and published by . This book was released on 2008-01-01 with total page 368 pages. Available in PDF, EPUB and Kindle. Book excerpt: Emphasizes the importance of early intervention in RA with focus on pharmacologic treatment of RA. Detailed information on the various medications employed in treatment, including corticosteroids, NSAIDs DMARDs, biologic agents, and combination therapy is reviewed, including evidence based data on efficacy, safety, side effects, and monitoring requirements. Clinical evaluation is presented, including lab findings, joint scoring, diagnostic criteria, and radiographic outcomes. Surgical options and the management of advanced RA are disussed.
Book Synopsis Fast Facts: Rheumatoid Arthritis by : John D. Isaacs
Download or read book Fast Facts: Rheumatoid Arthritis written by John D. Isaacs and published by Karger Medical and Scientific Publishers. This book was released on 2011-05-01 with total page 118 pages. Available in PDF, EPUB and Kindle. Book excerpt: This thoroughly updated second edition of 'Fast Facts: Rheumatoid Arthritis' provides an easy-to-read overview of how the condition is thought to develop and how it is diagnosed, monitored and treated. Written by two leading UK and US rheumatologists, it covers the many recent developments in this field, including: • Recently published classification criteria • The emerging role of anti-CCP autoantibodies • The latest developments in ultrasound and MRI • The association between RA and cardiovascular disease and lung disease • New concepts of undifferentiated arthritis and treatment to remission • The importance of early referral and new biological therapies 'Fast Facts: Rheumatoid Arthritis' provides a well-referenced international perspective on this condition. It is a 'must read' for all healthcare professionals caring for patients with this debilitating inflammatory joint disease. Contents: • The normal joint • Etiology • Pathogenesis • Epidemiology • Clinical features • Investigation • Assessment • Management - traditional measures • Management - biological therapies • Therapeutic developments
Book Synopsis Drug Therapy for Early Rheumatoid Arthritis by : Katrina E. Donahue
Download or read book Drug Therapy for Early Rheumatoid Arthritis written by Katrina E. Donahue and published by . This book was released on 2018 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: OBJECTIVES: Compare the benefits and harms of drug therapies for adults with early rheumatoid arthritis (RA) within 1 year of diagnosis, updating the findings on early RA from the 2012 review. DATA SOURCES: English-language articles identified through MEDLINE®, Cochrane Library, Embase®, International Pharmaceutical Abstracts, gray literature, the previous 2012 review, expert recommendations, reference lists of published literature, and supplemental evidence data requests from January 2011 to October 5, 2017. REVIEW METHODS: Literature was synthesized qualitatively in narrative form and summary tables within and between corticosteroids and classes of disease-modifying antirheumatic drugs (DMARDs). Additionally, combination treatment strategies were examined. We conducted network meta-analysis for five outcomes: American College of Rheumatology 50-percent improvement (ACR50), remission based on Disease Activity Score (DAS), radiographic joint damage, all discontinuations, and discontinuations due to adverse events. Eligibility for network meta-analyses required the following: (1) patients with early RA had not attempted prior treatment with methotrexate (MTX), (2) doses of treatments were within ranges approved by the Food and Drug Administration (FDA), (3) length of followup was similar, and (4) studies were double-blinded randomized controlled trials of low or medium risk of bias. RESULTS: We analyzed 49 studies: 41 RCTs and 8 observational studies reported in 124 published articles. All included studies enrolled patients with moderate to high disease activity at baseline as measured with mean or median DAS 28 scores. A combination of corticosteroids plus MTX achieved higher remission rates than with MTX monotherapy (low strength of evidence [SOE]). Combination therapy with TNF (tumor necrosis factor) or non-TNF biologics plus MTX improved disease control, remission, and functional capacity compared with monotherapy with either MTX or a biologic (low to moderate SOE). Network meta-analyses found higher ACR50 response for combination therapy of biologics plus MTX than for MTX monotherapy (range of relative risk, 1.20 [95% confidence interval (CI), 1.04 to 1.38] to 1.57 [95% CI, 1.30 to 1.88]). In available data, consisting mostly of clinical trials, no significant differences emerged between any DMARDs for rates of discontinuation attributable to adverse events or serious adverse events (low SOE for adalimumab, certolizumab pegol, etanercept, infliximab, or abatacept with MTX, and moderate SOE for rituximab or tocilizumab with MTX). Data about subgroups (based on disease activity, prior therapy, demographics, and the presence of other serious conditions) were insufficient. No difference in findings were noted in MTX naïve and resistant populations. We found no studies of biosimilars for patients with early RA. CONCLUSIONS: Qualitative synthesis and network meta-analyses suggest that the combination of MTX with TNF or non-TNF biologics improves disease activity and remission when compared with biologic monotherapy or a conventional synthetic DMARD (csDMARD) monotherapy in patients with moderate to high disease activity at baseline as measured with mean or median DAS 28 scores. Overall rates of adverse events and discontinuation were similar among patients given csDMARDs, TNF biologics, and non-TNF biologics. We did not find eligible studies of biosimilars.
Book Synopsis Safe and Effective Medicines for Children by : Institute of Medicine
Download or read book Safe and Effective Medicines for Children written by Institute of Medicine and published by National Academies Press. This book was released on 2012-10-13 with total page 432 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Book Synopsis A Clinician's Pearls & Myths in Rheumatology by : John H. Stone
Download or read book A Clinician's Pearls & Myths in Rheumatology written by John H. Stone and published by Springer Science & Business Media. This book was released on 2009-10-03 with total page 489 pages. Available in PDF, EPUB and Kindle. Book excerpt: Important strides have been made in understanding the pathophysiologic basis of many inflammatory conditions in recent years, but rheumatology remains a discipline in which diagnosis is rooted in the medical history skillfully extracted from the patient, the careful physical examination, and the discriminating use of laboratory tests and imaging. Moreover, selection of the most appropriate therapy for patients with rheumatic diseases also remains heavily reliant upon clinical experience. Medical disciplines such as rheumatology that depend significantly upon clinical wisdom are prone to the development of systems of ‘Pearls’ and ‘Myths,’ related to the diseases they call their own, a ‘Pearl’ being a nugget of truth about the diagnosis or treatment of a particular disease that has been gained by dint of clinical experience and a ‘Myth’ being a commonly held belief that influences the practice of many clinicians – but is false. This book will pool together the clinical wisdom of seasoned, expert rheumatologists who participate in the care of patients with autoimmune diseases, systemic inflammatory disorders, and all other rheumatic conditions.
Book Synopsis Encyclopedia of Medical Immunology by : Ian R. Mackay
Download or read book Encyclopedia of Medical Immunology written by Ian R. Mackay and published by . This book was released on 2019 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Offering a broad appeal to microbiologists, immunologists, and infectious disease specialists, this four volume encyclopedia covers all autoimmune, tropical, and infectious diseases. Emphasis will also be placed on genetics, physiology, metabolism, pathogenesis and applied microbiology. Under the leadership of some of the most world renowned names in the field, the encyclopedia will bring together an outstanding collection of contributions by top scientists in a variety of fields. Volumes 1-3: Diseases will be divided by the 11 main sections of the body, namely Integumentary, Skeletal, Respiratory, Digestive, Urinary, and Reproductive. For some of the autoimmune disease, more then one system will be involved but the delineation serves to broadly break down the diseases into systems. Volume 4 will cover the vaccines for said diseases and future prospects will be offered by leaders in industry and academia. Volume 4 will also be broken down into all the body systems, as in the other two volumes. For each vaccine, for each disease, and in each system the following will be included: • A list of the vaccines currently available along with a list of the companies that manufacture them • Molecular Immunology of the Vaccine • Type of Immunity involved in protection • Mode of Vaccination for each vaccine; repeated boosters and length of immunological memory • Commercial production of vaccines • Storage of vaccines • Standardization and Control of Vaccines • WHO programs and World-Wide Disease Eradication Programs based upon Vaccines.
Download or read book Early Arthritis written by Karen Torralba and published by Clinics: Internal Medicine. This book was released on 2012 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: To ensure the best possible clinical outcomes for arthritis patients, it is essential that they be seen early and treated appropriately at the earliest opportunity. Early therapy has proven much more effective than that given late. This issue of Rheumatic Disease Clinics of North America brings the rheumatologist up to date on the latest treatments and interventions in evolving arthritis and established early arthritis. Topics covered include early rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, oligoarthritis, osteoarthritis, and others. Imaging modalities are addressed as well as various contemporary treatments including biologics.
Book Synopsis Biologics in General Medicine by : W.-H. Boehncke
Download or read book Biologics in General Medicine written by W.-H. Boehncke and published by Springer Science & Business Media. This book was released on 2007-05-08 with total page 202 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is the first book to cover every angle in the clinical application of biologics. Readers will not only find that all of the biologics currently approved for clinical use are delineated in a standardized way, but also the "differential therapy" with biologics in fields including dermatology and neurology is described in detail and summarized in treatment algorithms. Shorter sections on biologic biotechnology as well as safety and regulatory issues complement the more clinically-oriented central chapters.
Book Synopsis A System of Medicine: pt. 1. Infective diseases, intoxications by : Thomas Clifford Allbutt
Download or read book A System of Medicine: pt. 1. Infective diseases, intoxications written by Thomas Clifford Allbutt and published by . This book was released on 1909 with total page 1116 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Biologic Response Modifier Agents as First-line Treatment for Patients with Rheumatoid Arthritis by :
Download or read book Biologic Response Modifier Agents as First-line Treatment for Patients with Rheumatoid Arthritis written by and published by . This book was released on 2013 with total page 48 pages. Available in PDF, EPUB and Kindle. Book excerpt: Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approximately 300,000 Canadians. It is characterized by pain, swelling and progressive joint damage, an increase in morbidity and mortality, and a reduction in quality of life and daily activities. Traditional disease modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX), leflunomide, sulfasalazine and hydroxychloroquine, have been shown to modify the clinical course of RA and to slow or stop radiographic progression. The newer biologic disease modifying agents target specific mechanisms of inflammation and have increased the therapeutic options for patients with RA. In Canada, these agents include the tumor necrosis factor (TNF) inhibitors (adalimumab, etanercept, infliximab, golimumab, and certolizumab), T cell costimulatory inhibitor (abatacept), B lymphocyte-depleting agent (rituximab), interleukin 6 antagonist (tocilizumab) and interleukin 1 inhibitor (anakinra). Based on a CADTH therapeutic review completed in 2010, biologic agents were recommended for use in adults with RA who had an inadequate response to optimal doses of DMARDs. Since that review, a number of studies have been published including trials in patients who are DMARD nav̐e. There are outstanding questions regarding the optimal use of biologic agents, as earlier and more aggressive treatment strategies are being used in clinical practice. This report will review the evidence on the clinical efficacy, cost-effectiveness and guidelines for use of biologic agents as first line therapy in adults with RA.
Book Synopsis The Handbook of Biological Therapy by : Bruce Kirkham
Download or read book The Handbook of Biological Therapy written by Bruce Kirkham and published by OUP Oxford. This book was released on 2008-11-27 with total page 176 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitioners using biologics. As the use of these drugs increases around the world, so the level of information needed by primary care practitioners and specialist prescribers needs to be expanded The Handbook of Biological Therapy provides the practising clinician with a practica guide to the use of Tumour Necrosis Factor Blocking Therapy (TNF-blockers), and important new class of biologic therapy for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. It is a comprehensive distillation of the authors' clinical experience with these drugs, combined with data from diverse databases offering practical advice on their uses, specific indications, supporting clinical trial data and safety issues, with the aim of making the use of these drugs easier for the busy clinician. All of the authors have been involved from the beginnings of the clinical trial programmes with these drugs and continue to use them in daily practice.
Book Synopsis Early Arthritis, An Issue of Rheumatic Disease Clinics by : Karen Torralba
Download or read book Early Arthritis, An Issue of Rheumatic Disease Clinics written by Karen Torralba and published by Elsevier Health Sciences. This book was released on 2012-05-28 with total page 216 pages. Available in PDF, EPUB and Kindle. Book excerpt: To ensure the best possible clinical outcomes for arthritis patients, it is essential that they be seen early and treated appropriately at the earliest opportunity. Early therapy has proven much more effective than that given late. This issue of Rheumatic Disease Clinics of North America brings the rheumatologist up to date on the latest treatments and interventions in evolving arthritis and established early arthritis. Topics covered include early rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, oligoarthritis, osteoarthritis, and others. Imaging modalities are addressed as well as various contemporary treatments including biologics.
Book Synopsis Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinics by : John J Cush
Download or read book Drug Safety: Managing Innovation in Rheumatology, An Issue of Rheumatic Disease Clinics written by John J Cush and published by Elsevier Health Sciences. This book was released on 2012-11-28 with total page 183 pages. Available in PDF, EPUB and Kindle. Book excerpt: Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today––drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.
